Today, we’re humbled and thrilled to share that A Race Against Blindness has awarded an additional $1 million grant to Axovia Therapeutics to help bring a gene therapy for Bardet-Biedl Syndrome 1 (BBS1) into its first clinical trial.
This grant represents more than a financial milestone — it’s proof of what a united community can achieve.
-
Since 2024, we’ve now awarded $4 million in total grants toward advancing AXV-101, an investigational therapy that aims to stop retinal degeneration in children with BBS1.
-
This achievement is powered by our incredible donor community and the generosity of our fundraiser sponsors, who donate goods and time so we can run the fundraisers that make this work possible.
Looking Back, Moving Forward
Our journey is one of persistence, hope, and community. You can read more about our progress, including prior grants, in our Annual Reports.
Thank you for believing in a future where blindness is not inevitable. Today’s milestone belongs to every donor, sponsor, and supporter who has joined the race against blindness.
This milestone was announced today via our official GlobeNewswire press release, and has since been picked up by Morningstar, highlighting the growing attention this research is receiving.
